Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 5:09 AM
Ignite Modification Date: 2025-12-25 @ 5:09 AM
NCT ID: NCT00524927
Eligibility Criteria: Inclusion Criteria: * Adult participants (18 years of age or older) * Able to give written informed consent * Anticipated episode(s) of incident pain related to planned BMB lasting no more than 30 minutes on average * Anticipated life expectancy of at least 1 month Pre-Exclusion Criteria: * Subjects with a clinical condition that may, in the opinion of the investigator, impact on the subject's ability to participate in the study, or on the study results * Participants who have had IV sedation/opioid on previous BMB and who wish to receive IV sedation/opioid on this occasion or who in the opinion of the BMB operator would be advised to receive IV sedation/opioid on this occasion * Concomitant use of other investigational agents * Concomitant use of nephrotoxic agents such as gentamicin * Uncontrolled INR (\>4) * Personal or familial hypersensitivity to fluorinated anaesthetics * Personal or familial malignant hyperthermia * Respiratory rate of less than 10 per minute * Has previously received methoxyflurane * Known pre-existing renal or hepatic impairment * Compromised Renal Function (creatinine ≥ 1.5 x ULNR) * Compromised Liver Function (bilirubin ≥ 2.5 x ULNR) Exclusion Criteria: * Premedication with anxiolytic (e.g. midazolam, diazepam) * Dosed with breakthrough dose of analgesic that may contribute to control of pain during the planned procedure
Healthy Volunteers: True
Sex: ALL
Minimum Age: 18 Years
Study: NCT00524927
Study Brief:
Protocol Section: NCT00524927